BIOG B Share Price Performance
SEK 131.00
25.50 (24.17%)
6.4% undervalued intrinsic discount
SEK 140.00
Fair Value
Price SEK 131.00
AnalystConsensusTarget SEK 140.00
Fair ValueSEK 140.00
Share Pricen/a
Narrative Update • May 05
BioGaia AB (publ) Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 20 Fair Values set on narratives written by author
BIOG B Community Narratives
AN
Fair Value
·Fair Value SEK 140 6.4% undervalued intrinsic discount
Expanding North American Demand Will Unlock New Health Trends
0users have liked this narrative
0users have commented on this narrative
12users have followed this narrative
Expanding North American Demand Will Unlock New Health Trends
Key Takeaways Expansion in direct sales and mainstream retail channels supports sustained growth as preventative health trends and demand for natural, clinically-proven products intensify globally. Increased investment in innovation, marketing, and clinical research is expected to drive margin expansion and diversification despite short-term earnings pressure.Read more
AN
SEK 140
6.4% undervalued intrinsic discount
Fair Value
Revenue
10.05% p.a.
Profit Margin
26.98%
Future PE
29.9x
Price in 2029
SEK 163.46
Trending Discussion
Recently Updated Narratives
AN
BIOG B: Extra Dividend And Margin Resilience Will Support Future Re Rating
Fair Value: SEK 140 6.4% undervalued intrinsic discount
12 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
BioGaia AB (publ) Key Details
Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
Jul 17, 2026
- 3.28
- 72.97%
- 21.49%
- 0%
About BIOG B
- Founded
- 1990
- Employees
- 242
- CEO
- WebsiteView website
BioGaia AB (publ), a healthcare company, develops, manufactures, markets and sells probiotic products for gut, oral, and immune health in Europe, the Middle East, Africa, the United States, the Asia-Pacific, Australia, and New Zealand. It operates through Pediatrics, Adult Health, and Other segments. The Pediatrics segment offers drops, oral rehydration solutions, and gut health tablets, as well as cultures that are used as an ingredient in infant formula and milk formula. Its Adult Health segment provides gut health tablets, bone health tablets, and oral health lozenges, as well as cultures, which are used as an ingredient in a licensee’s dairy product. The Other segment offers packaging solutions. It sells its products through distribution partners or through its own distribution channels. The company was incorporated in 1990 and is headquartered in Stockholm, Sweden.
